Nexalin Technology, Inc. announced on November 26, 2024, that its proprietary Deep Intracranial Frequency Stimulation (DIFS) technology was prominently featured in a newly published editorial in Psychotherapy and Psychosomatics. This peer-reviewed article provides validation of Nexalin’s ability to non-invasively treat challenging psychiatric conditions.
The editorial highlights the advantages of the company’s 15mA DIFS over traditional neurostimulation and neuromodulation devices. It notes that Nexalin’s technology delivers high-intensity frequency-based stimulation capable of activating critical deep brain regions such as the hippocampus, amygdala, and insula, unlike lower-intensity methods.
Supported by stereoelectroencephalography (SEEG) recordings, the findings reinforce Nexalin’s ability to address unmet needs in treating conditions like major depressive disorder (MDD) and chronic insomnia. This scientific validation strengthens the company’s competitive position in the rapidly growing neuromodulation market, projected to reach $11.0 billion by 2028.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.